Five Prime Therapeutics, Inc. (NASDAQ:FPRX) – Investment analysts at Jefferies Group cut their FY2017 earnings per share estimates for shares of Five Prime Therapeutics in a research note issued on Monday. Jefferies Group analyst E. Yang now anticipates that the biotechnology company will post earnings of ($5.84) per share for the year, down from their prior estimate of ($5.78). Jefferies Group currently has a “Buy” rating and a $52.00 target price on the stock. Jefferies Group also issued estimates for Five Prime Therapeutics’ Q4 2017 earnings at ($1.50) EPS, FY2018 earnings at ($6.65) EPS, FY2019 earnings at ($5.33) EPS, FY2020 earnings at ($4.56) EPS and FY2021 earnings at ($2.23) EPS.

Several other equities analysts have also recently issued reports on the company. Royal Bank Of Canada started coverage on Five Prime Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $41.00 price objective on the stock. BMO Capital Markets increased their target price on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Monday, October 16th. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $64.00.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/11/11/fy2017-eps-estimates-for-five-prime-therapeutics-inc-fprx-lowered-by-analyst.html.

Five Prime Therapeutics (FPRX) opened at $28.83 on Thursday. Five Prime Therapeutics has a one year low of $21.41 and a one year high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.19). The business had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.72) earnings per share.

In related news, Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $40.26, for a total transaction of $72,468.00. Following the transaction, the director now directly owns 1,200 shares of the company’s stock, valued at $48,312. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director William R. Ringo sold 600 shares of Five Prime Therapeutics stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the transaction, the director now directly owns 600 shares in the company, valued at $27,198. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,400 shares of company stock worth $175,666. 6.50% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. acquired a new position in shares of Five Prime Therapeutics in the 3rd quarter valued at $223,000. Creative Planning boosted its position in Five Prime Therapeutics by 0.8% during the 2nd quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 54 shares during the period. Rockefeller Financial Services Inc. acquired a new stake in Five Prime Therapeutics during the 2nd quarter worth about $210,000. Tudor Investment Corp ET AL boosted its position in Five Prime Therapeutics by 56.8% during the 1st quarter. Tudor Investment Corp ET AL now owns 8,033 shares of the biotechnology company’s stock worth $290,000 after acquiring an additional 2,910 shares during the period. Finally, Dupont Capital Management Corp acquired a new stake in Five Prime Therapeutics during the 3rd quarter worth about $341,000. Institutional investors and hedge funds own 84.08% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.